These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38818914)

  • 1. Drug-Drug Interaction Potential of Remimazolam Mediated by CYP 450, Transporters, and Protein Binding.
    Petersen KU; Schmalix W; Pesic M; Stöhr T
    Curr Drug Metab; 2024 May; ():. PubMed ID: 38818914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system.
    Freyer N; Knöspel F; Damm G; Greuel S; Schneider C; Seehofer D; Stöhr T; Petersen KU; Zeilinger K
    Drug Des Devel Ther; 2019; 13():1033-1047. PubMed ID: 31037028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Metabolism of the New Benzodiazepine Remimazolam.
    Schmalix W; Petersen KU; Pesic M; Stöhr T
    Curr Drug Metab; 2024; 25(2):164-173. PubMed ID: 38523539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxidoreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers.
    Hu K; Xiang Q; Wang Z; Sheng X; Li L; Liang Y; Zhao X; Ye X; Cui Y
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):22-29. PubMed ID: 32250057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
    Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
    Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remimazolam: A Review in Procedural Sedation.
    Lee A; Shirley M
    Drugs; 2021 Jul; 81(10):1193-1201. PubMed ID: 34196946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children.
    Gao YQ; Ihmsen H; Hu ZY; Sun W; Fang YB; Wang Z; Schüttler J; Jeleazcov C; Liu HC
    Br J Anaesth; 2023 Nov; 131(5):914-920. PubMed ID: 37739904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
    Schiller H; Huth F; Schuhler C; Drollmann A; Kaul M; Woessner R; Shah B; Weis W; End P
    Eur J Pharm Sci; 2022 May; 172():106155. PubMed ID: 35247543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
    Tornio A; Filppula AM; Backman JT
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms.
    Dmitriev AV; Rudik AV; Karasev DA; Pogodin PV; Lagunin AA; Filimonov DA; Poroikov VV
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters.
    Sun P; Liu K
    Curr Drug Metab; 2018; 19(13):1119-1129. PubMed ID: 30062958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation.
    Zhou J; Curd L; Lohmer LRL; Delpratt N; Ossig J; Schippers F; Stoehr T; Schmith VD
    Clin Transl Sci; 2021 Jul; 14(4):1554-1565. PubMed ID: 33768731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
    Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials.
    Pesic M; Stöhr T; Ossig J; Borkett K; Donsbach M; Dao VA; Webster L; Schippers F
    Drugs R D; 2020 Sep; 20(3):267-277. PubMed ID: 32757149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remimazolam: A Retrospective Study of Initial Safety and Recovery Data in Diverse Procedural Sedation.
    Johnson KL; Meyers JS; Mortensen GN; Steege JR; Mara KC; Brinkman NJ
    Clin Ther; 2024 Feb; 46(2):90-95. PubMed ID: 38071132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total intravenous anesthesia management with simultaneous use of remimazolam and propofol: A case series of three patients.
    Watanabe Y; Obara S; Inoue S
    SAGE Open Med Case Rep; 2023; 11():2050313X231204574. PubMed ID: 37811347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
    Preskorn SH
    J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.